News and Trends 21 Jun 2019 Will US Fecal Transplant Death Impact European Biotech? The death of a US patient from complications after a fecal transplant last week could have a major impact on microbiome research in Europe. The microbiome is a field with big potential for treating disease by targeting imbalances in the patient’s gut flora, such as by giving patients the stool bacteria of a healthy person […] June 21, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2019 This Biotech Transports Cell Therapies Without Needing a Freezer The biotech Atelerix, based in Newcastle, UK, can transport cell therapies between different locations with less cost and risk than current methods by encapsulating the cells in a specialized gel. Mission: To eliminate the need for costly cold storage in the cell transport process by preserving cells in a gel. This could save further costs […] June 21, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2019 Spider Silk Could Improve Organoids for Drug Development The Stockholm-based organoids company BioLamina has teamed up with the recombinant spider silk Stockholm startup Spiber Technologies to develop organoids that are more accurate tissue models than those used currently. Organoids are gaining popularity as a drug testing tool due to their capacity for modeling human tissue in 3D, which is more representative than 2D […] June 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2019 Scientists Grow Head and Neck Cancer Organoids to Personalize Chemotherapy A team of Dutch researchers has developed the first 3D organoids from patients’ head and neck cancer cells that can be kept alive for a long time, giving physicians a model to test which cancer treatments are the most effective for each patient. Head and neck cancer is an aggressive disease that often requires harsh […] June 19, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2019 EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved by the EU as a first-line treatment preventing the return of ovarian cancer after initial chemotherapy. The drug has already been approved by the EU and the FDA as a maintenance treatment for relapsed ovarian cancer, and as a therapy […] June 19, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Jun 2019 The Top 20 Industrial Biotechnology Companies in Europe Europe’s industrial biotechnology sector is driving a massive change from petrochemical processes to more sustainable alternatives. Here are the top industrial biotechnology companies in Europe making every industry greener. Industrial biotechnology draws from biology and the billions of years of evolution behind it to make the production of any chemical compound more efficient and more […] June 19, 2019 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jun 2019 Belgian Biotech’s €35M Series B to Fund Potential Type 1 Diabetes Cure The Belgian company Imcyse has raised €35M in a Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis. Imcyse will use the money to fund phase II trials of a peptide-based treatment for type 1 diabetes. The funds will also help the company to launch […] June 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jun 2019 Dutch Biotech Boosts Hepatitis B Vaccine Effectiveness Phase II results from Dutch biotech CyTuVax show its enhanced hepatitis B vaccine reduces non-responders by 13%. Around 15% of people receiving vaccines for hepatitis B fail to produce antibodies that protect them against the infection. These non-responders are often given more injections of the vaccine in an attempt to trigger the immune system, but […] June 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2019 Swiss Anti-Aging Treatment Gives the Elderly Healthier Muscles An anti-aging dietary supplement developed by the Swiss biotech Amazentis to combat age-related muscle weakening has improved the health of muscle cells in a first-in-human study. Mitochondria are parts of the cell that generate energy, and are important for muscle movement. As we age, damaged mitochondria begin to build up in muscle cells, possibly contributing […] June 17, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2019 First Gene Therapy for Beta Thalassemia Will Cost Over €1.5M Zynteglo, a gene therapy developed by the US company bluebird bio for the treatment of beta-thalassemia, will cost European healthcare systems more than €1.5M per patient. Following the approval of the treatment earlier this month, bluebird bio has now released the pricing plan of Zynteglo. Healthcare systems in Europe will need to pay €315,000 upfront, […] June 14, 2019 - 1 minutemin - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2019 French Biotech Raises €20M to Prevent Hearing Loss The hearing loss biotech Sensorion has issued bonds to raise €20M, which it will use to fund the phase II development for first-in-class drugs treating hearing loss and severe vertigo. The money will pay for phase II trials of Sensorion’s two most advanced treatments, which are small molecule drugs to treat sudden deafness and acute […] June 14, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Jun 2019 This Biotech Reduces Drug Side Effects Using Silica Gel Implants DelSiTech is a Finnish company developing injectable silica gel implants that release drugs slowly over time, causing fewer side effects and helping patients stick to their treatment regimen. Mission: To develop silica gels that slowly release drugs over time to treat conditions including HIV, hepatitis B, retinal disease and cancer. One big problem in chronic […] June 14, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email